Diffuse aggressive B-cell lymphomas

Advances in Anatomic Pathology

Volumn 16, Issue 4, 2009, Pages 216-235

  Said, Jonathan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Burkitt; Classification; Diffuse large B cell lymphoma; Hodgkin; Lymphoma; Non Hodgkin; World health organization 2008

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CD30 ANTIGEN; CD5 ANTIGEN; CHROMOGRANIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ENOLASE; ETOPOSIDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERFERON REGULATORY FACTOR 4; KERATIN ANTIBODY; LACTATE DEHYDROGENASE; LEUKOSIALIN; PREDNISONE; PROTEIN BCL 6; PROTEIN P53; RITUXIMAB; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR PAX5; TUMOR MARKER; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BONE MARROW METASTASIS; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EPSTEIN BARR VIRUS; GENE EXPRESSION PROFILING; GENE MUTATION; HISTIOCYTE; HISTOLOGY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOBLAST; IMMUNOBLASTIC LYMPHOMA; IMMUNOGLOBULIN GENE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; LYMPHOMATOID GRANULOMATOSIS; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; MORPHOLOGY; OUTCOME ASSESSMENT; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN LYMPHOMA; SURVIVAL TIME; T CELL LYMPHOMA; T LYMPHOCYTE; THYMUS LYMPHOMA;

BONE MARROW; BONE MARROW EXAMINATION; BURKITT LYMPHOMA; DIAGNOSIS, DIFFERENTIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDICTIVE VALUE OF TESTS; STROMAL CELLS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 68849119968     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181a9d5d2     Document Type: Review

References (147)

1. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26:3603-3613.
2. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346:235-242. (Pubitemid 34438862)
3. Coiffier B, Pfreundschuh M, Stahel R, et al. Aggressive lymphoma: improving treatment outcome with rituximab. Anticancer Drugs. 2002;13(suppl 2):S43-S50. (Pubitemid 36177363)
4. Hummel M, Anagnostopoulos I, Korbjuhn P, et al. Epstein-Barr virus infection patterns in malignant lymphoma. In: Tursz T, Pagano JS, Ablashi DV, et al, eds. The Epstein-Barr Virus and Associated Diseases. Berlin: John Libbey Eurotext Ltd.; 1993.
5. Hummel M, Anagnostopoulos I, Korbjuhn P, et al. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. J Pathol. 1995;175:263-271.
6. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110:972-978. (Pubitemid 47267436)
7. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.
8. Piris M, Brown DC, Gatter KC, et al. CD30 expression in non-Hodgkin's lymphoma. Histopathology. 1990;17:211-218.
9. Loddenkemper C, Anagnostopoulos I, Hummel M, et al. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. J Pathol. 2004;202:60-69. (Pubitemid 38072846)
10. Barrans SL, Fenton JA, Banham A, et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood. 2004;104:2933-2935. (Pubitemid 39434982)
11. Ehinger M, Linderoth J, Christensson B, et al. A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. Am J Clin Pathol. 2008;129:630-638. (Pubitemid 352029283)
12. Niitsu N, Okamoto M, Nakamura N, et al. Prognostic impact of chromosomal alteration of 3q27 on nodal B-cell lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 329 consecutive patients. Leuk Res. 2007;31:1191-1197. (Pubitemid 46873742)
13. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346. (Pubitemid 32691848)
14. Pescarmona E, De Sanctis V, Pistilli A, et al. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas. J Pathol. 1997; 183:281-286. (Pubitemid 27505212)
15. Muramatsu M, Akasaka T, Kadowaki N, et al. Rearrangement of the BCL6 gene in B-cell lymphoid neoplasms. Leukemia. 1997;11(suppl 3):318-320. (Pubitemid 27313521)
16. Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood. 2002;99:2285-2290. (Pubitemid 34525409)
17. Jerkeman M, Aman P, Cavallin-Stahl E, et al. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - A Nordic Lymphoma Group Study. Int J Oncol. 2002;20:161-165.
18. Arber DA, George TI. Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol. 2005;29:1549-1557.
19. Campbell J, Seymour JF, Matthews J, et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol. 2006;76:473-480.
20. Hodges GF, Lenhardt TM, Cotelingam JD. Bone marrow involvement in large-cell lymphoma. Prognostic implications of discordant disease. Am J Clin Pathol. 1994;101:305-311. (Pubitemid 24089577)
21. Chung R, Lai R, Wei P, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110:1278-1282. (Pubitemid 47281426)
22. Kremer M, Spitzer M, Mandl-Weber S, et al. Discordant bone marrow involvement in diffuse large B-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders. Lab Invest. 2003;83:107-114. (Pubitemid 36126055)
23. Robertson LE, Redman JR, Butler JJ, et al. Discordant bone marrow involvement in diffuse large-cell lymphoma: a distinct clinical-pathologic entity associated with a continuous risk of relapse. J Clin Oncol. 1991;9:236-242.
24. Talaulikar D, Dahlstrom JE, Shadbolt B, et al. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study. Pathology. 2007;39: 580-585. (Pubitemid 350135644)
25. De Paepe P, Achten R, Verhoef G, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol. 2005;23:7060-7068. (Pubitemid 46260293)
26. Engelhard M, Brittinger G, Huhn D, et al. Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood. 1997;89:2291-2297. (Pubitemid 27143274)
27. Haralambieva E, Pulford KA, Lamant L, et al. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. Br J Haematol. 2000; 109:584-591. (Pubitemid 30415186)
28. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511. (Pubitemid 30082188)
29. Bea S, Zettl A, Wright G, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood. 2005;106:3183-3190. (Pubitemid 41565917)
30. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004;350:1828-1837.
31. Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:995-1007. (Pubitemid 46638855)
32. Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106:1770-1777. (Pubitemid 41208593)
33. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991-9996. (Pubitemid 37087056)
34. Rosenwald A, Wright G, Chan WC, et al. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. N Engl J Med. 2002;346:1937-1947. (Pubitemid 34651353)
35. Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9:55-61. (Pubitemid 28125765)
36. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood. 2000;95:2084-2092. (Pubitemid 30151649)
37. Berglund M, Thunberg U, Amini RM, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 2005;18:1113-1120. (Pubitemid 41224503)
38. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood. 2003;101:78-84. (Pubitemid 36025890)
39. De Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - A Study From the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2007;25:805-812. (Pubitemid 350002880)
40. De Leon ED, Alkan S, Huang JC, et al. Usefulness of an immunohistochemical panel in paraffin-embedded tissues for the differentiation of B-cell non-Hodgkin's lymphomas of small lymphocytes. Mod Pathol. 1998;11:1046-1051. (Pubitemid 28525009)
41. De Leval L, Harris NL. Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance. Histopathology. 2003;43:509-528. (Pubitemid 38002340)
42. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
43. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol. 2006;208:714-723.
44. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109:4930-4935. (Pubitemid 46827791)
45. Veelken H, Vik Dannheim S, Schulte Moenting J, et al. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol. 2007;18:931-939. (Pubitemid 47054092)
46. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol. 2008;26: 447-454. (Pubitemid 351171698)
47. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997;90:244-251. (Pubitemid 27276568)
48. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 1996;87:265-272. (Pubitemid 26018392)
49. Iqbal J, Neppalli VT, Wright G, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:961-968. (Pubitemid 46638851)
50. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol. 1996;14: 2131-2138. (Pubitemid 26230116)
51. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.
52. Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997;337:529-534. (Pubitemid 27352019)
53. Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood. 1997;90:4078-4091. (Pubitemid 27484063)
54. Leroy K, Haioun C, Lepage E, et al. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol. 2002;13: 1108-1115. (Pubitemid 34885013)
55. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994;83:1460-1466. (Pubitemid 24081556)
56. Sohn SK, Jung JT, Kim DH, et al. Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. Am J Hematol. 2003;73:101-107. (Pubitemid 36578431)
57. Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99:815-821. (Pubitemid 34525540)
58. Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol. 1995; 147:207-216.
59. Amen F, Horncastle D, Elderfield K, et al. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Histopathology. 2007;51: 70-79. (Pubitemid 46976368)
60. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430. (Pubitemid 43855045)
61. Ueda C, Nishikori M, Kitawaki T, et al. Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma. Int J Hematol. 2004;79:52-54. (Pubitemid 38182202)
62. Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist. 2006;11: 384-392.
63. Achten R, Verhoef G, Vanuytsel L, et al. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology. 2002;40:31-45.
64. Delabie J, Vandenberghe E, Kennes C, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol. 1992;16:37-48.
65. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102:3753-3758. (Pubitemid 37409397)
66. Chittal SM, Brousset P, Voigt JJ, et al. Large B-cell lymphoma rich in T-cells and simulating Hodgkin's disease. Histopathology. 1991;19:211-220.
67. Fraga M, Sanchez-Verde L, Forteza J, et al. T-cell/histiocyte-rich large B-cell lymphoma is a disseminated aggressive neoplasm: differential diagnosis from Hodgkin's lymphoma. Histopathology. 2002;41:216-229. (Pubitemid 35013943)
68. Bouabdallah R, Mounier N, Guettier C, et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol. 2003; 21:1271-1277. (Pubitemid 46606403)
69. Brauninger A, Kuppers R, Spieker T, et al. Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. Blood. 1999;93:2679-2687. (Pubitemid 29181201)
70. Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006;107:3716-3723.
71. Montesinos-Rongen M, Siebert R, Deckert M. Primary lymphoma of the central nervous system: just DLBCL or not? Blood. 2009;113:7-10.
72. Montesinos-Rongen M, Van Roost D, Schaller C, et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood. 2004;103:1869-1875. (Pubitemid 38268985)
73. Montesinos-Rongen M, Kuppers R, Schluter D, et al. Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol. 1999;155:2077-2086.
74. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105: 3768-3785.
75. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol. 2003;27:1538-1545. (Pubitemid 37486615)
76. Geelen FA, Vermeer MH, Meijer CJ, et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol. 1998;16:2080-2085.
77. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105:3671-3678. (Pubitemid 40628215)
78. Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood. 2005;106:2491-2497. (Pubitemid 41510824)
79. Kuze T, Nakamura N, Hashimoto Y, et al. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(-) cases in Japanese population. Jpn J Cancer Res. 2000;91: 1233-1240. (Pubitemid 32042357)
80. Shimoyama Y, Oyama T, Asano N, et al. Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review. J Clin Exp Hematop. 2006;46:1-4.
81. Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol. 2003;27:16-26. (Pubitemid 36014895)
82. Oyama T, Yamamoto K, Asano N, et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res. 2007;13:5124-5132. (Pubitemid 47502080)
83. Cazals-Hatem D, Lepage E, Brice P, et al. Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol. 1996;20:877-888. (Pubitemid 26230752)
84. Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997;15:1646-1653. (Pubitemid 27167405)
85. Higgins JP, Warnke RA. CD30 expression is common in mediastinal large B-cell lymphoma. Am J Clin Pathol. 1999; 112:241-247. (Pubitemid 30212541)
86. Copie-Bergman C, Gaulard P, Maouche-Chretien L, et al. The MAL gene is expressed in primary mediastinal large B-cell lymphoma. Blood. 1999;94:3567-3575. (Pubitemid 29536153)
87. Copie-Bergman C, Plonquet A, Alonso MA, et al. MAL expression in lymphoid cells: further evidence for MAL as a distinct molecular marker of primary mediastinal large B-cell lymphomas. Mod Pathol. 2002;15:1172-1180. (Pubitemid 35435135)
88. Ferreri AJ, Campo E, Seymour JF, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol. 2004;127:173-183.
89. Ferry JA, Harris NL, Picker LJ, et al. Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors. Mod Pathol. 1988;1:444-452.
90. Murase T, Yamaguchi M, Suzuki R, et al. Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood. 2007;109:478-485. (Pubitemid 46105941)
91. Murase T, Nakamura S, Kawauchi K, et al. An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome. Br J Haematol. 2000;111:826-834. (Pubitemid 32101416)
92. Petitjean B, Jardin F, Joly B, et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am J Surg Pathol. 2002;26:724-732. (Pubitemid 34546937)
93. Aozasa K, Takakuwa T, Nakatsuka S. Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation. Adv Anat Pathol. 2005;12:324-331. (Pubitemid 44357150)
94. Iuchi K, Aozasa K, Yamamoto S, et al. Non-Hodgkin's lymphoma of the pleural cavity developing from longstanding pyothorax. Summary of clinical and pathological findings in thirty-seven cases. Jpn J Clin Oncol. 1989;19: 249-257.
95. Nakatsuka S, Yao M, Hoshida Y, et al. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol. 2002;20: 4255-4260. (Pubitemid 35191029)
96. Narimatsu H, Ota Y, Kami M, et al. Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol. 2007;18:122-128. (Pubitemid 46152511)
97. Myers JL, Kurtin PJ, Katzenstein AL, et al. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol. 1995;19:1300-1312.
98. Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer. 1979;43:360-373. (Pubitemid 9128841)
99. Wilson WH, Kingma DW, Raffeld M, et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood. 1996;87:4531-4537. (Pubitemid 26162358)
100. Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv. 1997;30:233-248. (Pubitemid 27371545)
101. Koss MN, Hochholzer L, Langloss JM, et al. Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients. Pathology. 1986;18:283-288. (Pubitemid 16002579)
102. Adam P, Katzenberger T, Seeberger H, et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol. 2003;27:1473-1476. (Pubitemid 37315202)
103. Chikatsu N, Kojima H, Suzukawa K, et al. ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC). Mod Pathol. 2003;16:828-832.
104. Delsol G, Lamant L, Mariame B, et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood. 1997;89:1483-1490. (Pubitemid 27097438)
105. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood. 2003;102:2568-2573. (Pubitemid 37193597)
106. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413-1420. (Pubitemid 27080006)
107. Flaitz CM, Nichols CM, Walling DM, et al. Plasmablastic lymphoma: an HIV-associated entity with primary oral manifestations. Oral Oncol. 2002;38:96-102.
108. Cioc AM, Allen C, Kalmar JR, et al. Oral plasmablastic lymphoma in AIDS patients are associated with human herpesvirus 8. Am J Surg Pathol. 2004;28:41-46. (Pubitemid 38031619)
109. Dong HY, Scadden DT, De Leval L, et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005;29:1633-1641. (Pubitemid 43754485)
110. Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28:736-747. (Pubitemid 38685887)
111. Scheper MA, Nikitakis NG, Fernandes R, et al. Oral plasmablastic lymphoma in an HIV-negative patient: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:198-206. (Pubitemid 41024899)
112. Schichman SA, McClure R, Schaefer RF, et al. HIV and plasmablastic lymphoma manifesting in sinus, testicles, and bones: a further expansion of the disease spectrum. Am J Hematol. 2004;77:291-295. (Pubitemid 39430709)
113. Hausermann P, Khanna N, Buess M, et al. Cutaneous plasmablastic lymphoma in an HIV-positive male: an unrecognized cutaneous manifestation. Dermatology. 2004; 208:287-290. (Pubitemid 38594556)
114. Ferrazzo KL, Mesquita RA, Aburad AT, et al. EBV detection in HIV-related oral plasmablastic lymphoma. Oral Dis. 2007;13:564-569.
115. Borenstein J, Pezzella F, Gatter KC. Plasmablastic lymphomas may occur as post-transplant lymphoproliferative disorders. Histopathology. 2007;51:774-777. (Pubitemid 350179408)
116. Gaidano G, Cerri M, Capello D, et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol. 2002;119:622-628. (Pubitemid 35366199)
117. Vega F, Chang CC, Medeiros LJ, et al. Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2005;18:806-815. (Pubitemid 40780514)
118. Chuang SS, Ye H, Du MQ, et al. Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH. Am J Clin Pathol. 2007;128:558-564. (Pubitemid 47584432)
119. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442.
120. Divine M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005;16: 1928-1935. (Pubitemid 41724282)
121. Boerma EG, Van Imhoff GW, Appel IM, et al. Gender and age-related differences in Burkitt lymphoma - epidemiological and clinical data from The Netherlands. Eur J Cancer. 2004; 40:2781-2787.
122. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009-3020.
123. Nakamura N, Nakamine H, Tamaru J, et al. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod Pathol. 2002;15:771-776. (Pubitemid 34787314)
124. Wright DH. Burkitt's lymphoma: a review of the pathology, immunology, and possible etiologic factors. Pathol Annu. 1971;6:337-363.
125. Danilov AV, Pilichowska M, Danilova OV, et al. AIDS-related Burkitt lymphoma-A heterogeneous disease? Leuk Res. 2008;32:1939-1941.
126. Davi F, Delecluse HJ, Guiet P, et al. Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin's lymphomas. Burkitt's Lymphoma Study Group. J Clin Oncol. 1998;16:3788-3795. (Pubitemid 29001531)
127. Carbone A, Gloghini A, Gaidano G, et al. AIDS-related Burkitt's lymphoma. Morphologic and immunophenotypic study of biopsy specimens. Am J Clin Pathol. 1995;103: 561-567.
128. Said JW, Hoyer KK, French SW, et al. TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma. Lab Invest. 2001;81: 555-564.
129. Teitell MA, Lones MA, Perkins SL, et al. TCL1 expression and Epstein-Barr virus status in pediatric Burkitt lymphoma. Am J Clin Pathol. 2005;124:569-575. (Pubitemid 41395638)
130. Harris NL, Horning SJ. Burkitt's lymphoma - the message from microarrays. N Engl J Med. 2006;354:2495-2498.
131. De Falco G, Leucci E, Lenze D, et al. Gene-expression analysis identifies novel RBL2/p130 target genes in endemic Burkitt lymphoma cell lines and primary tumors. Blood. 2007;110:1301-1307. (Pubitemid 47281429)
132. Bellan C, Lazzi S, Hummel M, et al. Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood. 2005;106: 1031-1036. (Pubitemid 41076450)
133. Bellan C, Lazzi S, De Falco G, et al. Burkitt's lymphoma: new insights into molecular pathogenesis. J Clin Pathol. 2003; 56:188-192. (Pubitemid 36308032)
134. Lindstrom MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol. 2002;12: 381-387.
135. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19:25-33. (Pubitemid 43250976)
136. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335-1342. (Pubitemid 350144150)
137. McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29:1652-1660.
138. Haralambieva E, Boerma EJ, Van Imhoff GW, et al. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma. Am J Surg Pathol. 2005;29:1086-1094. (Pubitemid 41045555)
139. Rodig SJ, Vergilio JA, Shahsafaei A, et al. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008;32:113-122.
140. Thangavelu M, Olopade O, Beckman E, et al. Clinical, morphologic, and cytogenetic characteristics of patients with lymphoid malignancies characterized by both t(14;18)(q32;q21) and t(8;14)(q24;q32) or t(8;22)(q24;q11). Genes Chromosomes Cancer. 1990;2:147-158. (Pubitemid 20314574)
141. Rudiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin's disease and related diseases ("grey zone" lymphoma). Ann Oncol. 1998;9(suppl 5):S31-S38. (Pubitemid 29049115)
142. Gonzalez CL, Medeiros LJ, Jaffe ES. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma. Am J Clin Pathol. 1991;96:81-89.
143. Garcia JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histopathology. 2005;47: 101-110. (Pubitemid 40978819)
144. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol. 2005;29:1411-1421. (Pubitemid 41513290)
145. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-862. (Pubitemid 37152922)
146. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871-3879. (Pubitemid 37486965)
147. Cazals-Hatem D, Andre M, Mounier N, et al. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): A GELA Study. Am J Surg Pathol. 2001;25:297-306. (Pubitemid 32174198)